• Profile

Efficacy of canagliflozin vs metformin in women with polycystic ovary syndrome: A randomized, open label, non‐inferiority trial

Diabetes, Obesity and Metabolism Nov 05, 2021

Cai M, Shao X, Xing F, et al. - A single center, prospective, randomized open-label (ratio 1:1) non-inferiority trial comparing the safety and efficacy of canagliflozin vs metformin in polycystic ovary syndrome (PCOS) patients with insulin resistance (IR).

  • Researchers administered either 100 mg (n = 33) canagliflozin daily or 1,500–2,000 mg metformin daily (n = 35) for 12 weeks to women aged 18–45 years with PCOS and IR.

  • Outcomes suggest non-inferiority of canagliflozin to metformin in lowering of HOMA-IR after 12 weeks of treatment.

  • Significant improvement in menstrual pattern, reduction in body weight and total fat mass, and lowering of triglyceride levels could be achieved by administering with both canagliflozin and metformin.

  • There were significant advantages in reducing uric acid and dehydroepiandrosterone sulfate levels in correlation with providing canagliflozin vs metformin.

  • The main adverse events in the metformin group and canagliflozin group were pruritus vulvae (9.09%) and gastrointestinal reaction (55.55%), respectively.

  • In view of the noninferiority of canagliflozin to metformin in PCOS patients with IR, researchers herein support considering sodium-glucose co-transporter 2 inhibitors as effective drugs in the treatment of PCOS patients with IR.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen